Spatially mapping the immune landscape of melanoma using imaging mass cytometryDan Moldoveanu, Ian R. Watson, Matthew Dankner et al.|Science Immunology|2022Cited by 131
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, April A. N. Rose, Mathieu Lajoie et al.|Clinical Cancer Research|2018Cited by 76
The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanomaDiana Berry, Ian R. Watson, Dan Moldoveanu et al.|Cell Reports|2025Cited by 7
Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinationsApril A. N. Rose, Peter M. Siegel, Matthew Dankner et al.|Molecular Cancer Therapeutics|2018Cited by 1
Raw CyTOF images associated with Moldoveanu et al. 2022, Science ImmunologyDan Moldoveanu, Ian R. Watson, LeeAnn Ramsay et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 1